Navigation Links
NCPA Statement on CVS Caremark-Aetna Agreement
Date:7/29/2010

ALEXANDRIA, Va., July 29 /PRNewswire-USNewswire/ -- In response to the agreement announced that CVS Caremark would provide pharmacy benefits to all 9.7 million lives covered by insurance giant Aetna, the National Community Pharmacists Association (NCPA) issued the following statement from Arlington, Texas pharmacy owner and NCPA President Joseph H. Harmison, PD:

(Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100106/DC33253LOGO)

"When it comes to putting its profits before patients, CVS Caremark is quite simply in a league of its own. In seeking Federal Trade Commission approval of the merger of retail giant CVS with the major pharmacy benefit manager Caremark, pledged to be agnostic as to where patients filled their prescriptions. That pledge has rung hollow as patients and local pharmacists complain of greater and greater pressure – or outright mandates – to switch prescriptions to CVS stores or Caremark mail order.

"Two criticisms lodged against CVS Caremark since the merger would appear to be particularly relevant to the Aetna agreement. First, the utilization of sensitive, private medical information for crass, marketing pitches. Second, the imposition of the ironically named 'Maintenance Choice' program, which can force patients to endure unreasonable requirements for their prescription medication, such as significant waits for mail order or long trips to the nearest CVS. Both problems have the potential to plague additional patients as a result of this agreement.

"The cries of protest against compromised care and unreasonable restrictions on patient choice are likely to only grow louder and more frequent with this agreement. Regrettably, Aetna customers and patients can anticipate a barrage of misleading sales pitches and complex schemes intended to camouflage CVS Caremark's history of over-promising and under-delivering on pharmacy savings.

"The U.S. Federal Trade Commission's competition and privacy bureaus and at least 24 states and municipalities are investigating CVS Caremark regarding the many anticompetitive, anti-consumer complaints raised by patients, Members of Congress and independent community pharmacists. NCPA will continue to work to support these and other investigations in the hopes the regulators will see the need to implement meaningful changes to protect the patient's choice of pharmacy and to restore meaningful pharmacy competition."

The National Community Pharmacists Association (NCPA®) represents America's community pharmacists, including the owners of more than 22,700 independent community pharmacies, pharmacy franchises, and chains. Together they represent an $88 billion health-care marketplace, employ over 65,000 pharmacists, and dispense over 40% of all retail prescriptions. To learn more go to www.ncpanet.org or read NCPA's blog, The Dose, at http://ncpanet.wordpress.com.


'/>"/>
SOURCE National Community Pharmacists Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
7. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
8. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
9. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
10. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
11. VA Statement on Smoking Cessation Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 6.35% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... 2017 , ... A recent report from the Wisconsin Institute ... 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools participating ... student test score performance, the report’s limited analyses fail to provide answers as ...
(Date:4/25/2017)... Las Vegas, NV (PRWEB) , ... April 25, ... ... teeth can now choose a modern procedure that achieves results in a fraction ... orthodontist in Las Vegas, NV, with Significance Dental Specialists, now offers this ...
(Date:4/25/2017)... Atlanta, GA (PRWEB) , ... April 25, 2017 , ... ... to their neck and back pain with a reputable physician in their area, announces ... The CRM protects patient information for patients who are looking for reputable physicians to ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... predictive analytics to its patient care management module. Using this new feature, sleep ... patient has been initiated on continuous positive airway pressure (CPAP), oral, or other ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... large animal healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, ... development and joint health in horses at the immunologic level. , The scientifically-developed ...
Breaking Medicine News(10 mins):